A.R.R., M.L., M.G.H., C.D.S., D.S., C.D.P., M.J.D., S.K., L.K., A.Y., Y.J.L., M.L., A. Shen, G.R.B., M.E., R.L.V., J.A.E., J.R.J., L.D.K.T., L.A., C.P., L.S., R.Z., K.B., A.A., A.R.F. and K.J. are stockholders and either current or previous employees at Gritstone bio, Inc. and may be listed as co-inventors on various pending patent applications related to the vaccine platform presented in this study. C.K. received honoraria from OncLive, Total Health, consults/has consulted for Scenic Immunology BV and has received research funding from Bristol Myers Squibb, Merus, Gritstone bio and Acrivon. C.-Y.L. consults/has consulted for AstraZeneca, Genentech, Histosonics, Incyte, Ipsen, QED, Transthera and Boston Scientific and is a speaker for AstraZeneca and Incyte. A.I.S. has a leadership role at NEXT Oncology Virginia; is a stockholder of Eli Lilly; has received honoraria from CytomX Therapeutics, AstraZeneca/MedImmune, Merck, Takeda, Amgen, Janssen Oncology, Novartis, Bristol Myers Squibb and Bayer; has consultant or advisory roles at Incyte, Amgen, Novartis, Mirati Therapeutics, Gritstone bio, Jazz Pharmaceuticals, Takeda, Janssen Research & Development, Mersana, Daiichi Sankyo/AstraZeneca, Regeneron, Lilly, Black Diamond Therapeutics, Sanofi, Array BioPharma, AstraZeneca/MedImmune, Bristol Myers Squibb and Blueprint Medicines; has received research funding from LAM Therapeutics, Regeneron, Roche, AstraZeneca, Boehringer Ingelheim, Astellas Pharma, MedImmune, Novartis, Incyte, Abbvie, Ignyta, Takeda, Macrogenics, CytomX Therapeutics, Astex Pharmaceuticals, Bristol Myers Squibb, Loxo, Arch Therapeutics, Gristone bio, Plexxikon, Amgen, Daiichi Sankyo, ADCT, Janssen Oncology, Mirati Therapeutics, Rubius, Mersana, Blueprint Medicines, Alkermes, Revolution Medicines, Medikine, Synthekine, Black Diamond Therapeutics, BluPrint Oncology, Nalo Therapeutics, Scorpion Therapeutics and ArriVent Biopharma. M.L.J.: financial interests, personal, advisory board: Astellas, Otsuka; financial interests, institutional, research grant: AbbVie, Acerta, Amgen, Apexigen, Arcus, Array, AstraZeneca, Atreca, Beigene, Birdie, Boehringer Ingelheim, Checkpoint Therapeutics, Guardant Health, Genocea, Hengrui, Immunocore, Incyte, Janseen, Jounce, Gritstone bio, Lycera, Merck, Mirati, Oncomed, Regeneron, Ribon, Sanofi, Shattuck Labs, Stem CentRx, Syndax, Takeda, Tarveda, TCR2 Therapeutics, University of Michigan and WindMIL. B.J.: financial interests, personal, advisory board: Gritstone bio, Inc., Incyte, Taiho Oncology; financial interests, personal, research grant: BMS, Syntrix. A.M.: financial interests, personal, advisory board: Taiho, Incyte. J.R.H.: financial interests, personal, advisory board: Ipsen, Merck and Acrotech Biopharma; financial interests, institutional, research grant: ARMO Biosciences, Halozyme, Amgen, Merck, AbbVie, Advaxis, Astellas, Forty Seven, Immunomedics, Lilly, Gritstone bio, GSK and Arcus. The other authors declare no competing interests.